Company Overview of CardioVascular BioTherapeutics, Inc.
CardioVascular BioTherapeutics, Inc., a development stage biopharmaceutical company, focuses on developing and marketing protein drug candidates used in the treatment of cardiovascular disease. The company uses an active pharmaceutical ingredient, the 141 acidic human form of fibroblast growth factor-1, in its drug candidates, which facilitates the growth of new blood vessels in the heart tissues and organs with an impaired vascular system. Its products under development include CVBT-141A, a Phase I clinical trial completed product for use in the treatment of severe coronary heart disease; and CVBT-141B, a Phase I clinical trial completed product for the treatment of wound healing; CVBT-141C...
9500 Hillwood Drive
Las Vegas, NV 89134
Founded in 1998
Key Executives for CardioVascular BioTherapeutics, Inc.
Co-Founder and Vice Chairman
Principal Investigator for Phase II Heart Trial
Compensation as of Fiscal Year 2012.
CardioVascular BioTherapeutics, Inc. Key Developments
SEC Revokes Registration Of Securities Of CardioVascular BioTherapeutics For Failure To Make Required Periodic Filings
May 2 12
On May 2, 2012, Securities and Exchange Commission (SEC or the commission) revoked the registration of each class of registered securities of CardioVascular BioTherapeutics, Inc. for failure to make required periodic filings with the Commission. Without admitting or denying the findings in the Order, except as to jurisdiction, which it admitted, the company consented to the entry of an Order Making Findings and Revoking Registration of Securities Pursuant to Section 12(j) of the Securities Exchange Act of 1934 as to company finding that it had failed to comply with Section 13(a) of the Securities Exchange Act of 1934 (Exchange Act) and Rules 13a-1 and 13a-13 there under and revoking the registration of each class of company’s securities pursuant to Section 12(j) of the Exchange Act.
SEC Orders Hearings On Registration Suspension Or Revocation Against CardioVascular BioTherapeutics For Failure To Make Required Periodic Filings
Apr 12 12
In conjunction with trading suspension, Securities and Exchange Commission (SEC or the commission) also instituted public administrative proceedings to determine whether to revoke or suspend for a period not exceeding twelve months the registration of each class of the securities of CardioVascular BioTherapeutics, Inc. for failure to make required periodic filings with the Commission. In this Order, the Division of Enforcement (Division) alleges that the company is delinquent in its required periodic filings with the Commission. In this proceeding, instituted pursuant to Exchange Act Section 12(j), a hearing will be scheduled before an Administrative Law Judge. At the hearing, the judge will hear evidence from the Division and the company to determine whether the allegations of the Division contained in the Order, which the Division alleges constitute failures to comply with Exchange Act Section 13(a) and Rules 13a-1 and 13a-13 there under, are true. The judge in the proceeding will then determine whether the registrations pursuant to Exchange Act Section 12 of each class of the securities of company should be revoked or suspended for a period not exceeding twelve months. The Commission ordered that the Administrative Law Judge in this proceeding issue an initial decision not later than 120 days from the date of service of the order instituting proceedings.
CardioVascular BioTherapeutics, Inc. Engages Malone Bailey LLP as Auditor
Jun 28 11
CardioVascular BioTherapeutics, Inc. announced that it has engaged the Certified Public Accounting Firm, Malone Bailey LLP, to audit the years ending December 31, 2008, 2009 and 2010 and to review the quarterly filings for 2009, 2010, and 2011.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|